Skip to main navigation. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Interested parties can access a live audio webcast on the Investors page of the Savara website at. Time:||12:00 p. m. ET|. Participants: RA Session II, President, Founder and CEO. Relapsed or Refractory Select B-Cell Malignancies Clinical Study. Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies :: (APTO. Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. Company Contact: SVP, Corporate Communications and Investor Relations. Executive Vice President, CFO. View Upcoming Events. Format: 40-minute live virtual presentation. Oppenheimer Healthcare is dedicated to finding and highlighting opportunities in Rare & Orphan Disease to investors.
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022. D. LifeSci Advisors, LLC. For more information, please visit Contacts. Released March 10, 2022 • 8:30 AM EST. Scientific Advisory Board. Aptose also will participate in a focused panel discussion: |Panel Title:||Treating CLL in the Age of Targeted Therapy|.
9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. D., Senior Vice President and Chief Business Officer, will participate in Oppenheimer & Co. Inc. 's Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 23, 2019 in New York. Inversago Pharma inc. Media: Real Chemistry. Webcast Presentation. Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit. Media Contact: Source: For conferences that offer replays, presentations will be made available for a limited time. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. Dec 1 – Dec 3, 2020. View source version on.